The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.
Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe.
The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca <AZN.L> has developed with Merck & Co Inc <MRK.N> as it faces competition from British rival GlaxoSmithKline <GSK.L> on cancer drugs.
Lynparza became the first marketed PARP drug with a U.S. approval for ovarian cancer in 2014. PARP inhibitors are a growing focus for drug research, with potential for use in breast, lung and prostate cancers.
Last week, GSK's cancer treatment Zejula, which is also a PARP inhibitor, won positive recommendation from the EU watchdog as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy.
Zejula competes with rival PARP inhibitors, a class of treatments that work by blocking enzymes involved in repairing damaged DNA, thereby helping kill cancer cells, from AstraZeneca and Clovis Oncology <CLVS.O>.
Monday's recommendation for approval from the EMA's Committee for Medicinal Products for Human Use (CMPH) comes after Lynparza won EU approval in July for treating a form of pancreatic cancer.
While final approvals are up to the European Commission, it generally follows the CHMP's recommendation and endorses them within a couple of months.
AstraZeneca also said it is exploring additional trials in metastatic prostate cancer for Lynparza, and expects to publish data on a separate late-stage trial in the second half of 2021.
(Reporting by Aakash Jagadeesh Babu and Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty and Alexander Smith)
